Drug-Eluting Stents for Treatment of Peripheral Artery Disease

被引：0
作者：
Kazeen Abdullah
Bassel Bou Dargham
Micah Steinbrecher
Bo Sun
Zhao Huiqiang
Houman Khalili
Emmanouil S. Brilakis
Subhash Banerjee
机构：
[1] University of Texas Southwestern Medical Center,
[2] Veterans Affairs North Texas Health Care System,undefined
[3] Beijing Friendship Hospital,undefined
[4] Minneapolis Heart Institute,undefined
来源：
American Journal of Cardiovascular Drugs | 2018年 / 18卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Endovascular intervention is a mainstay treatment of peripheral artery disease (PAD) in addition to aggressive risk factor modification and exercise programs in patients with favorable anatomy or in those who are considered too high risk for surgical intervention. Treatment with percutaneous transluminal angioplasty (PTA) and bare metal stents (BMS) has been limited by high rates of in-stent restenosis (ISR) requiring repeat revascularization. Drug-eluting stents (DES), developed and designed to reduce ISR, offer a promising solution to the current challenges in endovascular management of PAD. Several randomized clinical trials have shown improved short- and mid-term outcomes with DES as compared with both PTA and BMS. Herein we provide an up-to-date review of the current literature on DES use in PAD.
引用
收藏
页码：175 / 180
页数：5
相关论文
共 141 条
  • [1] Allison MA(2007)Ethnic-specific prevalence of peripheral arterial disease in the United States Am J Prev Med 32 328-333
  • [2] Ho E(2012)Associations between conventional cardiovascular risk factors and risk of peripheral artery disease in men JAMA 308 1660-1667
  • [3] Denenberg JO(2012)Medical therapy in peripheral artery disease Circulation 126 491-500
  • [4] Joosten MM(2017)2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary Vasc Med. 22 NP1-NP43
  • [5] Pai JK(2005)Restenosis after percutaneous angioplasty: the role of vascular inflammation Vasc Health Risk Manag. 1 73-78
  • [6] Bertoia ML(2001)Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model Circulation. 104 1188-1193
  • [7] Berger JS(2014)Drug delivering technology for endovascular management of infrainguinal peripheral artery disease JACC Cardiovasc Interv. 7 827-839
  • [8] Hiatt WR(2006)Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial J Endovasc Ther. 13 701-710
  • [9] Gerhard-Herman MD(2011)First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease J Vasc Surg 54 394-401
  • [10] Gornik HL(2010)Preventing leg amputations in critical limb ischemia with below-the-knee drug-eluting stents: the PaRADISE (PReventing Amputations using Drug eluting StEnts) trial J Am Coll Cardiol 55 1580-1589
12345678910